Format

Send to

Choose Destination
Sci Rep. 2015 May 15;5:10439. doi: 10.1038/srep10439.

Neurological morphofunctional differentiation induced by REAC technology in PC12. A neuro protective model for Parkinson's disease.

Author information

1
1] Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy [2] Laboratory of Molecular Biology and Stem Cell Engineering - National Institute of Biostructures and Biosystems, 40121, Bologna, Italy [3] Department of Regenerative Medicine, Rinaldi Fontani Institute, 50144, Florence, Italy.
2
1] Department of Regenerative Medicine, Rinaldi Fontani Institute, 50144, Florence, Italy [2] Research Department, Rinaldi Fontani Foundation - NPO, 50144, Florence, Italy.
3
Department of Clinical and Experimental Medicine, University of Sassari, 07100, Sassari, Italy.
4
1] Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy [2] Laboratory of Molecular Biology and Stem Cell Engineering - National Institute of Biostructures and Biosystems, 40121, Bologna, Italy.
5
Department of Biomedical Sciences, University of Sassari, 07100, Sassari, Italy.
6
1] Laboratory of Molecular Biology and Stem Cell Engineering - National Institute of Biostructures and Biosystems, 40121, Bologna, Italy [2] Stem Wave Institute for Tissue Healing (SWITH), Gruppo Villa Maria and Ettore Sansavini Health Science Foundation NPO, 48022, Lugo, Italy.

Abstract

Research for the use of physical means, in order to induce cell differentiation for new therapeutic strategies, is one of the most interesting challenges in the field of regenerative medicine, and then in the treatment of neurodegenerative diseases, Parkinson's disease (PD) included. The aim of this work is to verify the effect of the radio electric asymmetric conveyer (REAC) technology on the PC12 rat adrenal pheochromocytoma cell line, as they display metabolic features of PD. PC12 cells were cultured with a REAC regenerative tissue optimization treatment (TO-RGN) for a period ranging between 24 and 192 hours. Gene expression analysis of specific neurogenic genes, as neurogenin-1, beta3-tubulin and Nerve growth factor, together with the immunostaining analysis of the specific neuronal protein beta3-tubulin and tyrosine hydroxylase, shows that the number of cells committed toward the neurogenic phenotype was significantly higher in REAC treated cultures, as compared to control untreated cells. Moreover, MTT and Trypan blue proliferation assays highlighted that cell proliferation was significantly reduced in REAC TO-RGN treated cells. These results open new perspectives in neurodegenerative diseases treatment, particularly in PD. Further studies will be needed to better address the therapeutic potential of the REAC technology.

PMID:
25976344
PMCID:
PMC4432565
DOI:
10.1038/srep10439
[Indexed for MEDLINE]
Free PMC Article

Supplemental Content

Full text links

Icon for Nature Publishing Group Icon for PubMed Central
Loading ...
Support Center